Abstract 252P
Background
Uterine sarcomas (US) are a rare, heterogeneous group of malignancies that have rapid progressive clinical course and poor prognosis. We are reporting a retrospective review of clinico-pathological characteristics and outcome of therapy of these tumors in Qatar.
Methods
Retrospective records of 37 patients with US treated in Qatar between January 2010 and December 2016 were reviewed. They were stratified according to the age at diagnosis, menopausal status, ethnic group, pathological subtype of the tumor, grade, stage and treatment modalities (single vs combined modalities; surgical procedure, radiotherapy treatment, adjuvant and palliative chemotherapy. Diagnostic and pathology work was done in one facility. Treatment plan was discussed in MDT. The surgical treatment options were TAH with our without BSO. The chemotherapy we used is Docetaxel Gemcitabine in adjuvant setting as well as palliative treatment for metastatic cases. Radiotherapy was conducted via external beam irradiation followed by brachytherapy. Overall survival (OS) was obtained from the date of diagnosis to the date of death. For the patients who were alive, data was censored on the date of last follow up visit.
Results
For the reviewed 37 patients, the range of age was 23-64 years old with median age 47 years. LMS are representing the most frequent subtype seen in 15 patients (40%), ESS- 10 (28%), RMS 6 (16%), MMMT 2 (4 %) and non-specified 4 (12%). The stage of the disease at time of diagnosis was 1 in 26%, stage II in 48%, stage III in 11% and stage IV 15%. Total 23 patients underwent surgical resection, 12 patients (53%) simple hysterectomy and 11 (47%) TAH+BSO with LN dissection. 13 patients receivedchemotherapy, in 7 cases as adjuvant, in 4 combined with radiotherapy and in 2 cases as palliative. 13 patient received radiotherapy and brachytherapy. Median follow up time was 42 months. Thorough the time 10 patients died, 18 are still alive and 9 have lost follow up. The Kaplan Maier Curve showed median OS 40 months. Survival rate after one year was 79% and after 3 years 58%.
Conclusions
In this pattern of population where the majority of US presented in early stages (74%), 42% will die within the first 3 years which reflect the need for running big phase 3 trials for optimization of the treatment approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ashraf Fadlelseid.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract